Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men: The Copenhagen city heart study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1535-1540

  Wittrup, Hans H ^a   Tybjærg Hansen, Anne ^a,b   Steffensen, Rolf ^c   Deeb, Samir S ^d   Brunzell, John D ^d   Jensen, Gorm ^b   Nordestgaard, Børge G ^a,b,e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d UNIVERSITY OF WASHINGTON   (United States)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atherosclerosis; Coronary disease; Enzymes; Genes; Lipids

Indexed keywords

LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL ANALYSIS;

EID: 0033021054     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1535     Document Type: Article

References (38)

1. Brunzell J. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York. NY: McGraw-Hill Inc; 1995:1913-1932.
2. Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 1995;6:291-305.
3. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther. 1996;70:101-135.
4. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjærg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96:1737-1744.
5. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest. 1997;99:1606-1613.
6. Cooper DN, Krawczak M, Antonarakis SE. The nature and mechanisms of human gene mutation. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill Inc; 1995:259-291.
7. Yang WS, Nevin DN, Peng R, Brunzell JD, Deeb SS. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci U S A. 1995;92:4462-4466.
8. Mailly F, Tugrul Y, Reymer PWA, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlson A, Vallance D, Winder AF, Miller GJ, Kastelein JJP, Hamsten A, Olivecrona G, Humphries SE, Talmud PJ. A common variant in the gene for lipoprotein lipase (Asp9→Asn): functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1995;15:468-478.
9. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
10. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet. 1973;1:954-959.
11. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med. 1973;54:148-160.
12. Appleyard M, Hansen AT, Schnohr P, Jensen G, Nyboe J. The Copenhagen City Heart Study. Østerbroundersøgelsen: a book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). Scand J Soc Med. 1989;170:1-160.
13. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals: a case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation. 1997;95:2358-2367.
14. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455→A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease: a study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest. 1997;99:3034-3039.
15. Tybjærg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998;338:1577-1584.
16. Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. The national patient registry: evaluation of data quality. Ugeskr Laeger. 1995;157:3741-3745.
17. Talmud P, Tybjaerg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durrington P, Humphries S. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis. 1991;89:137-141.
18. Norusis MJ. SPSS for Windows: Base System User's Guide. release 7.5. Chicago. Ill: SPSS Inc; 1997.
19. Hosmer DW, Lemeshow S. Model-building strategies, and methods for logistic regression. In: Applied Logistic Regression. New York, NY: John Wiley & Sons: 1989:82-134.
20. Menard S. An introduction to logistic regression diagnostics. In: Applied Logistic Regression Analysis. Thousand Oaks. Calif: Sage Publications; 1995:58-79.
21. Khoury MJ, Beaty TH, Cohen BH. Fundamental epidemiologic concepts and approaches. In: Khoury MJ, Beaty TH, Cohen BH, eds. Fundamentals of Genetic Epidemiology. New York, NY: Oxford University Press Inc; 1993:55-81.
22. Austin MA. Plasma triglyceride and coronary heart disease. [Review]. Arterioscler Thromb. 1991;11:2-14.
23. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
24. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
25. Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PWA, Gagné SE, Jansen H, Seidell JC, Kromhout D, Jukema JW, Bruschke AVG, Boerwinkle E, Hayden MR. The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease: the Regress Study Group. Clin Genet. 1998;53:27-33.
26. Reilly SL, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I: pleiotropic effects on means and variances. Am J Hum Genet. 1991;49:1155-1166. [published correction appears in Am J Hum Genet. 1992;51:942].
27. Kessling A, Ouellette S, Bouffard O, Chamberland A, Betard C, Selinger E, Xhignesse M, Lussier-Cacan S, Davignon J. Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones. Am J Hum Genet. 1992;50:92-106.
28. de Bruin TW, Mailly F, van Barlingen HH, Fisher R, Cabezas MC, Talmud P, Dallinga-Thie GM, Humphries SE. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur J Clin Invest. 1996;26:631-639.
29. Elbein SC, Yeager C, Kwong LK, Lingam A, Inoue I, Lalouel J-M, Wilson DE. Molecular screening of the lipoprotein lipase gene in hypertriglyceridemic members of familial noninsulin-dependent diabetes mellitus families. J Clin Endocrinol Metab. 1994;79:1450-1456.
30. Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ, Faergeman O. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. Circulation. 1997;96: 733-740.
31. Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JHC, Bruschke AVG, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJP. The Asp9Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis: the Regress Study. Circulation. 1996;94: 1913-1918.
32. Mailly F, Fisher RM, Nicaud V, Luong L-A, Evans AE, Marques-Vidal P, Luc G, Arveiler D, Bard JM, Poirier O, Talmud PJ, Humphries SE. Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM study. Atherosclerosis. 1996;122:21-28.
33. Zhang Q, Cavanna J, Winkelman BR, Shine B, Gross W, Marz W, Galton DJ. Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. Clin Genet. 1995;48:293-298.
34. Ehrenborg E, Clee SM, Pimstone SN, Reymer PWA, Benlian P, Hoogendijk CF. Davis HJ, Bissada N, Miao L, Gagné SE, Greenberg LJ, Henry R, Henderson H, Ordovas JM, Schaefer EJ, Kastelein JJP, Kotze MJ, Hayden MR. Ethnic variation and in vivo effects of the -93t→g promoter variant in the lipoprotein lipase gene. Arterioscler Thromb Vasc Biol. 1997;17:2672-2678.
35. Hall S, Chu G, Miller G, Cruickshank K, Cooper JA, Humphries SE, Talmud PJ. A common mutation in the lipoprotein lipase gene promoter, -93T/G, is associated with lower plasma triglyceride levels and increased promoter activity in vitro. Arterioscler Thromb Vasc Biol. 1997;17:1969-1976.
36. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardmen J, Kotite L, Kunitake ST, Havel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994; 14:1767-1774.
37. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15:534-542.
38. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.